Japan’s Teijin Sues Towa Over Generic Too Similar To Teijin Drug
This article was originally published in PharmAsia News
Two Japanese drug makers are involved in a legal battle over a generic maker's container design, which the suing company says was too similar to its own. Teijin Pharma filed the suit against Towa Pharmaceutical over its generic to Teijin's hay fever treatment, Rhinocort Powder Spray for Nasal Use. The suit accuses Towa of unfair competition by mimicking its packaging and method for dispensing the drug, which are too much like Teijin's. Teijin seeks an injunction and nearly $88,000 in damages. (Click here for more - a subscription may be required
You may also be interested in...
With some studies about to finish and others on clinical hold, the coronavirus vaccine field approaches an infection point as the US FDA prepares for its first advisory committee on the topic. Our charts and graphics offer a quick look at what stands where.
Funds will be used to expand European sales of the CE-marked Lenire device, scale-up manufacturing and progress US regulatory and reimbursement plans.
RB CEO Laxman Narasimhan sees the potential for the company to establish a global supplements business built on the successes it has enjoyed in the US and China. The comments came as RB reported solid growth in the third quarter, despite struggles for its OTC brands.